Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
1.870
-0.020 (-1.06%)
Jun 12, 2025, 4:00 PM - Market closed
Soligenix Revenue
Soligenix had revenue of $2.34K in the twelve months ending March 31, 2025, down -99.67% year-over-year. In the year 2024, Soligenix had annual revenue of $119.37K, down -85.78%.
Revenue (ttm)
$2.34K
Revenue Growth
-99.67%
P/S Ratio
2,564.64
Revenue / Employee
$146
Employees
16
Market Cap
6.01M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 119.37K | -719.99K | -85.78% |
Dec 31, 2023 | 839.36K | -109.55K | -11.55% |
Dec 31, 2022 | 948.91K | 124.64K | 15.12% |
Dec 31, 2021 | 824.27K | -1.54M | -65.07% |
Dec 31, 2020 | 2.36M | -2.27M | -49.04% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SNGX News
- 6 days ago - Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewsWire
- 4 weeks ago - Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results - PRNewsWire
- 2 months ago - Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - PRNewsWire
- 2 months ago - IBN Initiates Coverage of Soligenix Inc. - GlobeNewsWire
- 2 months ago - Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PRNewsWire
- 2 months ago - Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - PRNewsWire
- 3 months ago - HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - PRNewsWire
- 4 months ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire